Argus upgrades Pfizer to Buy, citing GLP-1 pipeline, oncology programs

Argus upgraded Pfizer (PFE) to Buy from Hold with a $35 price target The firm is positive on the company’s recent additions to its GLP-1 pipeline along with its “robust” programs in oncology and hematology, saying it has greater confidence in Pfizer’s ability to grow the top and bottom lines in post-2028 period, the analyst tells investors in a research note. Beyond 2028, Argus notes Pfizer’s accelerated R&D, successful launch of new products and bolt-on business development.